New antibody injection aims to tackle blinding eye diseases
NCT ID NCT05919693
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called EYE103, given as an injection into the eye, for people with diabetic macular edema (DME) or wet age-related macular degeneration (NVAMD). The trial had two parts: first, checking safety at increasing doses in about 12 people, then comparing two doses for effectiveness in about 80 people. The main goal was to see if the drug is safe and can improve vision.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EYE103 (a lab-made antibody given as an eye injection)
- What this could lead to
- If successful, EYE103 could offer a new treatment option for two common causes of vision loss, potentially reducing the need for frequent eye injections.
- What could go wrong
- This is an early-phase trial with only 33 participants, so results may not apply to everyone. The drug is injected directly into the eye, which carries risks like infection or inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA (DME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abilene, TX
Abilene, Texas, 79606, United States
-
Amarillo, TX
Amarillo, Texas, 79109, United States
-
Arecibo, PR
Arecibo, PR, 00612, Puerto Rico
-
Austin, TX
Austin, Texas, 78705, United States
-
Bakersfield, CA
Bakersfield, California, 93309, United States
-
Bellaire, TX
Bellaire, Texas, 77401, United States
-
Caba, Argentina
Caba, 1023, Argentina
-
Ciudad Autonoma Buenos Aires
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1121ABB, Argentina
-
Colorado Springs, Colorado
Colorado Springs, Colorado, 80909, United States
-
Dallas, TX
Dallas, Texas, 75231, United States
-
Germantown, TN
Germantown, Tennessee, 38138, United States
-
Hagerstown, MD
Hagerstown, Maryland, 21740, United States
-
Katy, TX
Katy, Texas, 77494, United States
-
Knoxville, TN
Knoxville, Tennessee, 37922, United States
-
Lakewood, CO
Lakewood, Colorado, 80288, United States
-
Lemont, NV
Lemont, Illinois, 60439, United States
-
London, England
London, England, NW10 7NS, United Kingdom
-
London, UK
London, W1G7LB, United Kingdom
-
McAllen, TX
McAllen, Texas, 78503, United States
-
Modesto, CA
Modesto, California, 95356, United States
-
Mountain View, CA
Mountain View, California, 94040, United States
-
Nashville, TN
Nashville, Tennessee, 37203, United States
-
Phoenix, AZ
Phoenix, Arizona, 85032, United States
-
Plano, TX
Plano, Texas, 75075, United States
-
Pompano Beach
Pompano Beach, Florida, 33064, United States
-
Reno, NV
Reno, Nevada, 89502, United States
-
Round Rock, TX
Round Rock, Texas, 78681, United States
-
Sacramento, CA
Sacramento, California, 95825, United States
-
Sacramento, CA
Sacramento, California, 95841, United States
-
San Antonio, TX
San Antonio, Texas, 78240, United States
-
The Woodlands, TX
The Woodlands, Texas, 77384, United States
-
West Columbia, SC
West Columbia, South Carolina, 29169, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new eye injection beat the current standard for diabetic vision loss?
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss
- New dosing strategy could mean fewer eye injections for Diabetes-Related vision loss
- New syringe could simplify High-Dose eye treatment
- Eye scan showdown: faricimab vs ranibizumab in diabetic retinopathy